BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 240 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q3 2022. The put-call ratio across all filers is 0.45 and the average weighting 1.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $43,438,000 | -67.3% | 287,350 | -68.5% | 0.08% | -65.3% |
Q2 2022 | $132,725,000 | -51.2% | 910,892 | -60.3% | 0.22% | -35.7% |
Q1 2022 | $271,980,000 | +28.4% | 2,293,843 | +49.2% | 0.34% | +46.2% |
Q4 2021 | $211,880,000 | – | 1,537,480 | – | 0.24% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 2,111,111 | $144,294,000 | 54.16% |
Knoll Capital Management, LLC | 856,844 | $58,565,000 | 38.16% |
ORACLE INVESTMENT MANAGEMENT INC | 2,123,271 | $145,126,000 | 21.73% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 860,261 | $58,799,000 | 6.01% |
ARS Investment Partners, LLC | 561,442 | $38,375,000 | 4.46% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $12,057,000 | 3.19% |
Eventide Asset Management | 2,015,000 | $137,725,000 | 2.04% |
Avidity Partners Management LP | 1,049,800 | $71,754,000 | 1.98% |
SILVERARC CAPITAL MANAGEMENT, LLC | 50,089 | $3,424,000 | 1.87% |
Nicholas Investment Partners, LP | 375,654 | $25,676,000 | 1.79% |